Abstract
Purpose
To evaluate whether non-opioid antipyretic analgesics are associated with lower pain scores, opioid doses and side effects in pain patients in tertiary care.
Methods
In a cross-sectional observational study, data from 519 Caucasians (197 men, 322 women; mean age 55.6 ± 15 years) who had undertaken pain therapy for various causes for 77.5 ± 90.8 months, obtained in three separate study centres, was analysed for actual 24-h pain scores, daily opioid doses and the occurrence of side effects.
Results
Of the 519 patients, 352 received opioids and 260 antipyretic analgesics, from whom 154 received both classes and 304 only either class. The administration of non-opioid antipyretic analgesics was associated with higher average pain scores (4.6 ± 2.5 vs 3.9 ± 2.6; P = 0.01), tendentially higher average oral morphine equivalent doses (121.8 ± 162.2 vs 146.7 ± 242.4 mg/d; P = 0.25) and a similar incidence of side effects (P = 0.21). These results were correspondingly seen when analysing the three study centres separately as independent cohorts.
Conclusions
With the caution advised for cross-sectional data, the results dispute a clinical benefit of non-opioid antipyretic analgesics for most chronic pain patients in tertiary care and draw attention towards prospectively re-evaluating the utility of non-opioid antipyretic analgesics in tertiary pain care in a randomised placebo controlled trial.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
McQuay HJ, Moore RA, Eccleston C, Morley S, Williams AC. Systematic review of outpatient services for chronic pain control. Health Technol Assess. 1997;1(6):1–135.
Picard P, Bazin JE, Conio N, Ruiz F, Schoeffler P. Ketorolac potentiates morphine in postoperative patient-controlled analgesia. Pain. 1997;73(3):401–6.
Filitz J, Ihmsen H, Gunther W, Troster A, Schwilden H, Schuttler J, et al. Supra-additive effects of tramadol and acetaminophen in a human pain model. Pain. 2008;136(3):262–70.
Remy C, Marret E, Bonnet F. Effects of acetaminophen on morphine side-effects and consumption after major surgery: meta-analysis of randomized controlled trials. Br J Anaesth. 2005;94(4):505–13.
Mercadante S. The use of anti-inflammatory drugs in cancer pain. Cancer Treat Rev. 2001;27(1):51–61.
Chen JY, Ko TL, Wen YR, Wu SC, Chou YH, Yien HW, et al. Opioid-sparing effects of ketorolac and its correlation with the recovery of postoperative bowel function in colorectal surgery patients: a prospective randomized double-blinded study. Clin J Pain. 2009;25(6):485–9.
Marret E, Kurdi O, Zufferey P, Bonnet F. Effects of nonsteroidal antiinflammatory drugs on patient-controlled analgesia morphine side effects: meta-analysis of randomized controlled trials. Anesthesiology. 2005;102(6):1249–60.
Elia N, Lysakowski C, Tramer MR. Does multimodal analgesia with acetaminophen, nonsteroidal antiinflammatory drugs, or selective cyclooxygenase-2 inhibitors and patient-controlled analgesia morphine offer advantages over morphine alone? Meta-analyses of randomized trials. Anesthesiology. 2005;103(6):1296–304.
Eisenberg E, Berkey CS, Carr DB, Mosteller F, Chalmers TC. Efficacy and safety of nonsteroidal antiinflammatory drugs for cancer pain: a meta-analysis. J Clin Oncol. 1994;12:2756–65.
Lötsch J, von Hentig N, Freynhagen R, Griessinger N, Zimmermann M, Doehring A, et al. Cross-sectional analysis of the influence of currently known pharmacogenetic modulators on opioid therapy in outpatient pain centers. Pharmacogenet Genomics. 2009;19(6):429–36.
Doehring A, Freynhagen R, Griessinger N, Zimmermann M, Sittl R, von Hentig N, et al. Cross-sectional assessment of consequences of a GTP cyclohydrolase 1 haplotype for specialized tertiary outpatient pain care. Clin J Pain. 2009;25(9):781–5.
Hinz B, Cheremina O, Brune K. Acetaminophen (paracetamol) is a selective cyclooxygenase-2 inhibitor in man. FASEB J. 2008;22(2):383–90.
Pierre SC, Schmidt R, Brenneis C, Michaelis M, Geisslinger G, Scholich K. Inhibition of cyclooxygenases by dipyrone. Br J Pharmacol. 2007;151(4):494–503.
Twycross R, Wilcock A. Palliative care formulary. 3rd ed. Oxford: Palliativebooks.com; 2007.
Lienert GA. Applied configural frequency analysis. A reader on typological research in psychology and medicine. Frankfurt am Main: Athenäum; 1988.
Serhan CN, Chiang N, Van Dyke TE. Resolving inflammation: dual anti-inflammatory and pro-resolution lipid mediators. Nat Rev Immunol. 2008;8(5):349–61.
Yacoubian S, Serhan CN. New endogenous anti-inflammatory and proresolving lipid mediators: implications for rheumatic diseases. Nat Clin Pract Rheumatol. 2007;3(10):570–9.
Choi SH, Aid S, Bosetti F. The distinct roles of cyclooxygenase-1 and -2 in neuroinflammation: implications for translational research. Trends Pharmacol Sci. 2009;30(4):174–81.
Brenneis C, Coste O, Angioni C, Schmidt H, Altenrath K, Schuh C-D, et al. Anti-inflammatory role of microsoaml prostaglandin synthase-1 in a model of neuroinflammation. J Biol Chem. 2010. (in revision).
Scholich K, Geisslinger G. Is mPGES-1 a promising target for pain therapy? Trends Pharmacol Sci. 2006;27(8):399–401.
Blaho VA, Buczynski MW, Brown CR, Dennis EA. Lipidomic analysis of dynamic eicosanoid responses during the induction and resolution of lyme arthritis. J Biol Chem. 2009;284(32):21599–612.
Acknowledgment
We thank Mark Sellen for native English language editing.
Author information
Authors and Affiliations
Corresponding author
Additional information
Responsible Editor: Michael Parnham.
Rights and permissions
About this article
Cite this article
Lötsch, J., Freynhagen, R., von Hentig, N. et al. Higher pain scores, similar opioid doses and side effects associated with antipyretic analgesics in specialised tertiary pain care. Inflamm. Res. 59, 989–995 (2010). https://doi.org/10.1007/s00011-010-0215-3
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00011-010-0215-3